Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07322341CT.gov SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07388524CT.gov Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | — | Not Yet Recruiting | — | — | — |
NCT07195695CT.gov Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | — | Recruiting | — | — | — |
NCT06908993CT.gov Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated | — | Recruiting | — | — | — |
NCT06066138CT.gov A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | — | Recruiting | — | — | — |
NCT07093762CT.gov Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07130032CT.gov Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade | — | Recruiting | — | — | — |
NCT07153445CT.gov Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06731270CT.gov Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy | — | Recruiting | — | — | — |
NCT06616623CT.gov Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
Show 138 more trialsShow fewer
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05859217CT.gov A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) | — | Not Yet Recruiting | — | — | — |
NCT06422403CT.gov A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers | — | Recruiting | — | — | — |
NCT06463665CT.gov Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | — | Recruiting | — | — | — |
NCT06444815CT.gov A Study of VET3-TGI in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT06332755CT.gov Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC | — | Recruiting | — | — | — |
NCT06267001CT.gov A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy | — | Terminated | — | — | — |
NCT05798663CT.gov Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC | — | Active Not Recruiting | — | — | — |
NCT05689671CT.gov Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05935774CT.gov OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05867121CT.gov A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 | — | Completed | — | — | — |
NCT05746481CT.gov Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | — | Terminated | — | — | — |
NCT04691817CT.gov Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy | — | Recruiting | — | — | — |
NCT06097962CT.gov Safety and Efficacy of NK510 to Treat NSCLC | — | Recruiting | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT05825625CT.gov NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | — | Active Not Recruiting | — | — | — |
NCT06090318CT.gov Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | — | Withdrawn | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT05781308CT.gov Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT05295212CT.gov Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB | — | Recruiting | — | — | — |
NCT05340309CT.gov Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05259319CT.gov Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) | — | Unknown | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05317858CT.gov Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | — | Recruiting | — | — | — |
NCT05334329CT.gov Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05047250CT.gov A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05395052CT.gov FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04467723CT.gov Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC | — | Recruiting | — | — | — |
NCT05171777CT.gov A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05240131CT.gov A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | — | Unknown | — | — | — |
NCT04958811CT.gov Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC | — | Active Not Recruiting | — | — | — |
NCT05034055CT.gov Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04984811CT.gov NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | — | Terminated | — | — | — |
NCT05007769CT.gov Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC | — | Withdrawn | — | — | — |
NCT04919369CT.gov All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04911166CT.gov Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy | — | Terminated | — | — | — |
NCT04989283CT.gov Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04639245CT.gov Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04611776CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04776447CT.gov Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | — | Active Not Recruiting | — | — | — |
NCT04563338CT.gov An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE) | — | Active Not Recruiting | — | — | — |
NCT04832854CT.gov A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04267237CT.gov A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03915678CT.gov Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04480372CT.gov SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II | — | Completed | — | — | — |
NCT04310020CT.gov Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04865250CT.gov Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT04619797CT.gov A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04512430CT.gov Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | — | Terminated | — | — | — |
NCT04432207CT.gov A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04302025CT.gov A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT04591431CT.gov The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | — | Unknown | — | — | — |
NCT04440735CT.gov A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04471428CT.gov Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy | — | Completed | — | — | — |
NCT04549428CT.gov Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC | — | Terminated | — | — | — |
NCT04245085CT.gov ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | — | Completed | — | — | — |
NCT04426825CT.gov A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04471415CT.gov Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04513925CT.gov A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT04214262CT.gov Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04449874CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | — | Active Not Recruiting | — | — | — |
NCT04099836CT.gov Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib | — | Terminated | — | — | — |
NCT04367311CT.gov Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA) | — | Active Not Recruiting | — | — | — |
NCT04147351CT.gov A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. | — | Completed | — | — | — |
NCT04194203CT.gov A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | — | Completed | — | — | — |
NCT04294810CT.gov A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03896074CT.gov Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT) | — | Active Not Recruiting | — | — | — |
NCT04042558CT.gov A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | — | Completed | — | — | — |
NCT04081688CT.gov Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | — | Terminated | — | — | — |
NCT03977467CT.gov Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor | — | Completed | — | — | — |
NCT03991403CT.gov Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | — | Unknown | — | — | — |
NCT03977194CT.gov Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03922997CT.gov A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03689855CT.gov Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC | — | Completed | — | — | — |
NCT03836066CT.gov Atezolizumab Plus Bevacizumab in First Line NSCLC Patients | — | Completed | — | — | — |
NCT03976518CT.gov Atezolizumab in Advanced Non-small Cell Lung Cancer With Rare Histologies (CHANCE Trial) | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03782207CT.gov A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice | — | Active Not Recruiting | — | — | — |
NCT03829501CT.gov A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies | — | Terminated | — | — | — |
NCT03801304CT.gov Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03735121CT.gov A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT03600701CT.gov Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03713944CT.gov Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03647956CT.gov Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | — | Unknown | — | — | — |
NCT03644823CT.gov Combinatory ImmunoTherapy-1 (Com-IT-1) Irradiation and PD-1 Blockade in Locally Advanced / Advanced NSCLC | — | Terminated | — | — | — |
NCT03563716CT.gov A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03455556CT.gov Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03616691CT.gov Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC | — | Unknown | — | — | — |
NCT03568656CT.gov Study to Evaluate CCS1477 in Advanced Tumours | — | Completed | — | — | — |
NCT03526900CT.gov Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis | — | Completed | — | — | — |
NCT03498222CT.gov Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | — | Withdrawn | — | — | — |
NCT03559647CT.gov The Effectiveness Of Atezolizumab In Patients With Locally-Advanced Or Metastatic Non-Small Cell Lung Cancer After Prior Chemotherapy | — | Completed | — | — | — |
NCT03520686CT.gov Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02599454CT.gov Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03456063CT.gov A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | — | Completed | — | — | — |
NCT03438318CT.gov Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03511391CT.gov CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | — | Completed | — | — | — |
NCT03337698CT.gov A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | — | Terminated | — | — | — |
NCT03289962CT.gov A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | — | Completed | — | — | — |
NCT03232593CT.gov A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | — | Completed | — | — | — |
NCT03102242CT.gov Atezolizumab Immunotherapy in Patients With Advanced NSCLC | — | Completed | — | — | — |
NCT03285763CT.gov A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03178552CT.gov A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03191786CT.gov A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy | — | Completed | — | — | — |
NCT03170960CT.gov Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02919449CT.gov Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab | — | Terminated | — | — | — |
NCT03014648CT.gov Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03050060CT.gov Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer | — | Terminated | — | — | — |
NCT03138889CT.gov Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT02314481CT.gov Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity | — | Completed | — | — | — |
NCT02927301CT.gov A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3) | — | Completed | — | — | — |
NCT03228368CT.gov The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients | — | Unknown | — | — | — |
NCT03035890CT.gov Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03023423CT.gov A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02994576CT.gov Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02848651CT.gov A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02813785CT.gov A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy | — | Completed | — | — | — |
NCT02716038CT.gov Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | — | Completed | — | — | — |
NCT02657434CT.gov A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | — | Completed | — | — | — |
NCT02630186CT.gov A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT02525757CT.gov MPDL3280A With Chemoradiation for Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02400814CT.gov MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02486718CT.gov Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010] | — | Active Not Recruiting | — | — | — |
NCT02543645CT.gov A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | — | Terminated | — | — | — |
NCT02463994CT.gov A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC | — | Completed | — | — | — |
NCT02409342CT.gov A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] | — | Completed | — | — | — |
NCT02495636CT.gov Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT02409355CT.gov A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | — | Terminated | — | — | — |
NCT02367781CT.gov A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02366143CT.gov A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02298153CT.gov A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma | — | Terminated | — | — | — |
NCT02013219CT.gov A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02008227CT.gov A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy | — | Completed | — | — | — |
NCT02031458CT.gov A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01903993CT.gov A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | — | Completed | — | — | — |
NCT01846416CT.gov A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | National Cancer Institute (NCI) | Approved | BB · 67 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →